Vectura, Unilever Establish Specialty Pharmaceutical Company
This article was originally published in The Pink Sheet Daily
Executive Summary
PharmaKodex will apply novel oral and dermal delivery mechanisms to existing therapies.
You may also be interested in...
Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.
Novartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.